Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.

A live webcast will be available via the Investors section of the company website at investors.connectbiopharma.com, with an archived replay accessible for approximately 90 days after the conference.

Key Figures

Cash & investments: $54.8M Net loss: $17.2M Operating expenses: $17.7M +5 more

8 metrics

Cash & investments $54.8M As of Sept 30, 2025 (Q3 2025 10-Q)

Net loss $17.2M Q3 2025 (three months ended Sept 30, 2025)

Operating expenses $17.7M Q3 2025 total operating expenses

R&D expense $11.1M Q3 2025 research and development

G&A expense $6.6M Q3 2025 general and administrative

Loss per share $0.31 Q3 2025 basic and diluted loss per share

Shares outstanding 55,903,513 Ordinary shares outstanding as of Oct 31, 2025

Beneficial ownership 10.8% Wubin Pan stake as of Dec 31, 2025 (Schedule 13G/A)

Market Reality Check

Price: $2.93 Vol: Volume 118,755 vs 20-day ...

normal vol

$2.93 Last Close

Volume Volume 118,755 vs 20-day average 95,558 (relative volume 1.24x). normal

Technical Price $2.93 trading above 200-day MA $1.81, within 52-week range $0.51–$3.28.

Peers on Argus

CNTB was up 3.17% with modestly elevated volume, while only one close peer (STTK...

1 Up

CNTB was up 3.17% with modestly elevated volume, while only one close peer (STTK) appeared in momentum scans, up about 4.24%. Other biotech peers saw single‑digit gains, but scanner data did not indicate a broad, synchronized sector move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	MOA/data update	Positive	-1.4%	Highlighted new rademikibart mechanism data and outlined 2026 clinical priorities.
Nov 24	Conference participation	Neutral	-4.3%	Announced fireside chat at the 8th Annual Evercore Healthcare Conference.
Nov 12	Earnings update	Positive	+5.9%	Reported Q3 2025 results and business update with ongoing Phase 2 programs.
Sep 29	Clinical data update	Positive	-16.6%	Presented Phase 2b rademikibart data with significant FEV1 gains and fewer exacerbations.
Sep 04	Conference preview	Neutral	-10.6%	Announced two upcoming ERS 2025 poster presentations on rademikibart in asthma.

Pattern Detected

Recent scientific and mechanism-of-action updates often coincided with negative next-day moves, whereas the latest earnings and business update saw a positive reaction, suggesting mixed trading responses to news versus data-heavy disclosures.

Recent Company History

Over the past six months, CNTB has focused on rademikibart and respiratory indications. Key events included ERS 2025 data showing lung-function gains and reduced exacerbations, multiple conference presentations, and a Q3 2025 update noting $54.8M in cash and expected runway into 2027. Several data and conference announcements saw negative next-day moves, while the November 2025 earnings and business update drew a positive reaction. Today’s Oppenheimer conference appearance fits the pattern of ongoing visibility efforts rather than a discrete clinical or financial catalyst.

Market Pulse Summary

This announcement highlights CNTB’s participation in the Oppenheimer conference, extending its patte...

Analysis

This announcement highlights CNTB’s participation in the Oppenheimer conference, extending its pattern of using investor and medical meetings to spotlight rademikibart and its inflammatory-disease pipeline. Against a backdrop of prior ERS data releases, Q3 2025 results showing a $17.2M net loss and $54.8M in cash, and sizable disclosed shareholders, investors may focus on upcoming Phase 2 readouts and capital needs rather than this visibility-focused event alone.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26^th, 2026 at 2:40 p.m. ET.

The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802

Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

FAQ

When will Connect Biopharma (CNTB) present at the Oppenheimer Healthcare Life Sciences conference?

Connect Biopharma will present on Thursday, February 26, 2026 at 2:40 p.m. ET. According to the company, management plans to deliver the presentation at that scheduled time during the Oppenheimer 36th Annual Healthcare Life Sciences Conference.

How can investors watch Connect Biopharma's (CNTB) Oppenheimer conference presentation?

Investors can watch a live webcast at investors.connectbiopharma.com at the scheduled time. According to the company, the live stream will be accessible via the Investors section of its website for real‑time viewing.

Will Connect Biopharma (CNTB) provide a replay of the Oppenheimer presentation and for how long?

Yes, an archived replay will be posted and available for approximately 90 days following the conference. According to the company, the replay will be hosted on the investor website for on‑demand access during that period.

What topics will Connect Biopharma (CNTB) cover at the February 26, 2026 presentation?

The company will present management remarks and updates relevant to its clinical-stage programs and strategy. According to the company, the presentation will cover recent developments and corporate outlook for investors at the conference.

Where is the webcast of Connect Biopharma's (CNTB) presentation hosted?

The webcast is hosted on the company's investor website at investors.connectbiopharma.com. According to the company, both the live webcast and the archived replay will be available through that Investors section.

Is the Connect Biopharma (CNTB) Oppenheimer presentation open to the public or only to registered attendees?

The presentation will be available via a public live webcast on the investor website, enabling remote access. According to the company, viewers can watch the session online without attending the conference in person.